 |
Journal articles
18F-FDG PET/CT evaluation of Ceritinib therapy in metastatic ALK-positive non-small cell lung cancer
Abstract : Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancers (NSCLC) account for 3% to 7% of all NSCLC and require a standard treatment by crizotinib. However, crizotinib resistance is frequent within the first 12 months of treatment. Ceritinib is a novel tyrosine kinase inhibitor of ALK recently introduced in France for metastatic or locally advanced crizotinib-resistant ALK NSCLC. We report the first use of ceritinib in our institution with a spectacular tumoral response after only 3 months of treatment. This case demonstrates the major role of F-FDG PET/CT for monitoring the effectiveness of this new treatment.
https://hal.univ-reims.fr/hal-01822370
Contributor : Nicolas Passat Connect in order to contact the contributor
Submitted on : Monday, June 25, 2018 - 8:55:29 AM
Last modification on : Wednesday, November 3, 2021 - 6:53:59 AM
Contributor : Nicolas Passat Connect in order to contact the contributor
Submitted on : Monday, June 25, 2018 - 8:55:29 AM
Last modification on : Wednesday, November 3, 2021 - 6:53:59 AM